The VTose Platform for broad-spectrum antiviral development

Driven by a desire to reduce suffering in the world, Kimer Med has taken on this challenge. Since our founding in 2020, we’ve built and tested an internal platform for the rapid development of modular, broad-spectrum antivirals. Using our platform, we’ve created antiviral compounds that, to date, have shown broad-spectrum efficacy against a range of different viruses, including Dengue and Zika.

We are in the process of conducting further testing against more human viruses, and planning for in vivo (animal) studies before we begin Phase 1 clinical trials. In August 2023 we launched our Series A capital round to raise the necessary funds to conduct clinical trials, and eventually to bring these life-saving antiviral drugs to market. Our work - Kimer Med Broad-spectrum antivirals